We are live on ! Find out more
PHIO icon

Phio Pharmaceuticals
PHIO

6 hedge funds and large institutions have $220K invested in Phio Pharmaceuticals in 2023 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

3% more capital invested

Capital invested by funds: $213K → $220K (+$6.5K)

0.34% more ownership

Funds ownership: 0.04% → 0.38% (+0.34%)

40% less funds holding

Funds holding: 10 → 6 (-4)

50% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 2

80% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 5

Holders
6
Holders Change
-4
Holders Change %
-40%
% of All Funds
0.1%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
1
Reduced
2
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors
Iowa
+$83.5K
2
Renaissance Technologies
Renaissance Technologies
New York
+$2.27K

Top Sellers

Rank Fund Capital Flow
1
Geode Capital Management
Geode Capital Management
Massachusetts
-$39K
2
Cetera Investment Advisers
Cetera Investment Advisers
Illinois
-$27.9K
3
Vanguard Group
Vanguard Group
Pennsylvania
-$15.3K
4
UBS Group
UBS Group
Switzerland
-$10K
5
Two Sigma Investments
Two Sigma Investments
New York
-$8.33K

PHIO Hedge Fund Activity: Q1 2023 in Review

6 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Phio Pharmaceuticals (PHIO) for Q1 2023, worth a combined $220K — up 3.1% from $213K a quarter earlier.

Sellers outnumbered buyers: 5 funds closed out of PHIO and 1 opened new positions — a net loss of 4 holders — while 2 trimmed existing stakes and 1 added.

The largest buyer was Cambridge Investment Research Advisors, opening a new position worth an estimated $83.5K. The largest seller was Geode Capital Management, exiting entirely with an estimated $39K sold.

  • 6 institutional investors held Phio Pharmaceuticals (PHIO) as of Q1 2023, down from 10 in Q4 2022.
  • Funds reported $220K of Phio Pharmaceuticals stock for Q1 2023, up 3.1% quarter-over-quarter.
  • 1 fund opened new Phio Pharmaceuticals positions in Q1 2023 and 5 closed out, a net change of -4 holders.
  • The largest Phio Pharmaceuticals buyer in Q1 2023 was Cambridge Investment Research Advisors, an estimated $83.5K added.
  • The largest Phio Pharmaceuticals seller in Q1 2023 was Geode Capital Management, an estimated $39K sold.

Based on aggregated 13F filings for Q1 2023.